内克塔治疗 NKTR 深 沪
等待开盘 01-30 09:30:00 美东时间
35.23
-0.680
-1.89%
华盛通- 最 高36.20
- 今 开35.65
- 成交量 49.80万股
- 最 低 34.82
- 昨 收 35.91
- 总市值 7.17亿
- 52周最高 66.92
- 市盈率 静 --
- 换手率 2.45%
- 52周最低 6.48
- 委 比 60.00%
- 总股本 2034.16万
- 历史最高 1670.40
- 量 比 0.71
- 振 幅 3.84%
- 历史最低 6.189
- 每 手 1
- 风险率 19.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
今天 10:54
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $118 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $118 price target.
今天 01:00
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Reports Sale of Common Shares
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Reports Sale of Common Shares Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
01-23 08:32
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna, Inc. announced the appointment of Mark A. Wilson as Chief Legal Officer. With over 25 years of experience in intellectual property, corporate law, and strategic collaborations, Wilson joins from Nektar Therapeutics, where he served as Senior Vice President and Chief Legal Officer. His expertise is expected to strengthen Septerna’s governance and maximize the value of its Native Complex Platform™, which advances GPCR drug discovery. Wils...
01-08 21:05
FlexShares International Quality Dividend Index Fund declares quarterly distribution of $0.4694
FlexShares International Quality Dividend Index Fund (IQDF) - $0.4694. Payable Dec 26; for shareholders of record Dec 19; ex-div Dec 19. More on Oracle Q2 Earnings: Don't Catch The Falling Knife Itali...
2025-12-19 23:53
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.
2025-12-17 00:30
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qua...
2025-12-06 07:00
Citigroup Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $102
Citigroup analyst Samantha Semenkow initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $102.
2025-11-27 03:17
Nektar Therapeutics Reveals Promising Phase 2b Trial Results
Nektar Therapeutics ( ($NKTR) ) has provided an update. On November 8, 2025, Ne...
2025-11-10 19:58
